

## UC Irvine Division of Nephrology, Hypertension & Kidney Transplantation, Department of Medicine Kidney Biopsy Conference Kidney Biopsy Conference

November 4, 2026 – 4:30 PM

Teleconference

---

### **Target Audience**

Specialties – Anesthesiology & Perioperative Care, Dermatology, Emergency Medicine, Family Medicine, Medicine, Neurological Surgery, Neurology, Obstetrics & Gynecology, Ophthalmology, Orthopaedic Surgery, Otolaryngology - Head & Neck Surgery, Pathology & Laboratory Medicine, Pediatrics, Physical Medicine & Rehabilitation, Plastic Surgery, Psychiatry & Human Behavior, Radiation Oncology, Radiological Sciences, Surgery, Urology, Other  
Professions – Physician, Physician Assistant, Resident Physician

### **Objectives**

**At the conclusion of this activity, the participant should be able to:**

- 1 Analyze recent advances in research in the field of internal medicine including the speaker's research in terms of clinical relevance.
- 2 Inspect basic science or clinically relevant research findings and developments through a representative case presentation.
- 3 Critically analyze data from clinical research findings or updated care guidelines and apply it to the care of patients.

### **Faculty & Planner Disclosures**

University of California, Irvine School of Medicine Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

| Name of individual | Individual's role in activity | Nature of Relationship(s) / Name of Ineligible Company(s)                                                                                                                                         |
|--------------------|-------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Ramy Hanna, MD     | Co-Director                   | Speakers Bureau-Alexion<br>Pharmaceuticals   Consulting Fee-<br>Novartis Corporation<br>Pharmaceuticals   Honoraria-Otsuka<br>America Pharmaceutical, Inc.<br>(Relationship has ended)   Speakers |

|                                                |                      |                                                                                                                                                                                                                                                                                                                                                                                  |
|------------------------------------------------|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                |                      | Bureau-AstraZeneca (Any division)   Speakers Bureau-Aurinia   Honoraria-GSK (Relationship has ended)   Speakers Bureau-Calliditas   Independent Contractor (included contracted research)-Roche (Any division)   Independent Contractor (included contracted research)-Apellis   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Remegen - 03/22/2026 |
| Stefaney Mendoza, BA                           | Activity Coordinator | Nothing to disclose - 06/18/2026                                                                                                                                                                                                                                                                                                                                                 |
| John Sy, MD                                    | Course Director      | Nothing to disclose - 10/06/2026                                                                                                                                                                                                                                                                                                                                                 |
| Ekamol Tantisattamo, MD, MPH, FACP, FASN, FAHA | Course Director      | Nothing to disclose - 08/17/2026                                                                                                                                                                                                                                                                                                                                                 |
| Steven Vasquez                                 | Activity Coordinator | Nothing to disclose - 06/24/2026                                                                                                                                                                                                                                                                                                                                                 |
| Jonathan Zuckerman, MD, PhD                    | Faculty              | Consulting Fee-Leica Biosystems (Relationship has ended)   Advisor-Amgen, Inc.   Advisor-Vera Therapeutics   Advisor-Appellis pharmaceuticals - 03/24/2026                                                                                                                                                                                                                       |

## **Accreditation Statement**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

## **Designation Statement**

The University of California, Irvine School of Medicine designates this activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **ADA Statement**

In compliance with the Americans with Disabilities Act, we will make every reasonable effort to accommodate your request. For any special requests, please contact the department administrator before the meeting dates.

## **California Assembly Bill 1195 and 241**

This activity is in compliance with California Assembly Bill 1195 and 241, which require CME activities with patient care components to include curriculum in the subjects of cultural and linguistic competency & implicit bias. It is the intent of AB 1195 and AB 241 to encourage physicians and surgeons, CME providers in the State of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population and reduce health disparities.

# UCI School of Medicine

through appropriate professional development. Please see the CME website, <https://medschool.uci.edu/cme>, for AB 1195 and AB 241 resources.

## MOC Statement(s)



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. ABMS